Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Exelixis, Inc.NASDAQ: EXEL

Gross Profit · Q2 FY2026 · quarter ended Jul 2026

Gross profit grows in line with its trailing trend

Q2 FY2026 gross profit of $608.03M rose 10.8% year over year, ahead of the +9.1% change in trailing-twelve-month gross profit. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.

Context

  • Gross profit amounted to 96.4% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +10.8% holds above the trailing-twelve-month pace of +9.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
$608.03M+2.9% QoQ
Last fiscal yearJan 2026
$2.24B+6.9% YoY
LTMJul 2026
$2.35B+9.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.8%——
1 year+6.9%——
3-year CAGR+12.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
2.24B USD
Year-over-year change
+6.9%
4-year CAGR
+12.8%

Gross Profit vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 gross profit of $2.35B is the 4th highest of the 8 companies compared; the peer median is $279.95M.
  • Its year-over-year change of +9.1% is the 4th highest of 6, against a peer median of +26.6%.
  • Gross profit amounts to 96.5% of revenue for EXEL, versus a peer median of 92.8%.
EXEL Competitors Peer median
Gross Profit for EXEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$49.79B +4.0%+14.6%80.1%
INCYIncyte CorporationLTM Jun 2026$5.39B +26.6%+14.4%92.6%
GMABGenmab A/SLTM Jun 2026$3.84B —-38.3%93.0%
EXELExelixis, Inc.LTM Jul 2026$2.35B +9.1%+12.9%96.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$279.95M +53.8%+32.3%93.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$212.73M +396.6%—98.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$53.76M -70.5%+22.6%8.9%
RVMDRevolution Medicines, Inc.LTM Jun 2026-$9.24M ———
Peer median (excluding EXEL) $279.95M+26.6%+14.6%92.8%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.43B1.61B1.83B2.17B2.32B
Cost of Revenue52.87M57.91M72.55M76.22M83.7M
Gross Profit1.38B1.55B1.76B2.09B2.24B
Gross Margin96.3%96.4%96.0%96.5%96.4%
Research & Development693.72M891.81M1.04B910.41M825M
Selling, General & Admin401.72M459.86M542.71M492.13M518.73M
Operating Expenses1.1B1.35B1.59B1.49B1.36B
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
EBITDA307.78M255.23M283.24M718.75M921.76M
EBITDA Margin21.4%15.8%15.5%33.1%39.7%
Operating Income286.67M201.48M170.89M604.62M872.19M
Operating Margin20.0%12.5%9.3%27.9%37.6%
Interest Income7.67M33.07M86.54M77.16M69.21M
Interest Expense00000
Other Income / Expenses7.49M32.87M86.64M77.02M69.02M
Income Before Tax294.15M234.35M257.52M681.64M941.21M
Pre-Tax Margin20.5%14.5%14.1%31.4%40.6%
Income Tax Expense63.09M52.07M49.76M160.37M158.64M
Net Income231.06M182.28M207.77M521.27M782.57M
Net Margin16.1%11.3%11.4%24.0%33.7%
EPS (Basic)0.730.570.651.802.88
EPS (Diluted)0.720.560.651.762.78
Weighted Avg Shares314.88M321.53M318.15M290.03M271.57M
Weighted Avg Shares (Diluted)322.36M324.56M321.46M296.13M281.86M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.